Reducing delayed intensification therapy in childhood ALL. (Q44190259)

30 November 2017

Reducing delayed intensification therapy in childhood ALL. (English)

1 reference

30 November 2017

Ching-Hon Pui

1

1 reference

30 November 2017

8 February 2013

1 reference

Lancet Oncology Commission

30 November 2017

1 reference

30 November 2017

14

1 reference

30 November 2017

3

1 reference

30 November 2017

178-179

1 reference

Treating childhood acute lymphoblastic leukemia without cranial irradiation

30 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970001-9

7 January 2021

Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970001-9

7 January 2021

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970001-9

7 January 2021

Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970001-9

7 January 2021

Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970001-9

7 January 2021

Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970001-9

7 January 2021

Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970001-9

7 January 2021

Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970001-9

7 January 2021

10.1016/S1470-2045(13)70001-9

Identifiers

DOI

1 reference

30 November 2017

1 reference

PubMed ID

23402706